Drug discovery and development
The latest chemistry news and research on drug discovery and development, including cancer drugs, antibiotics, vaccines and drug screening, from the Royal Society of Chemistry's magazine, Chemistry World
-
ResearchControlling variability in biosynthesis: the role of high-purity solvents and reagents
From oligonucleotides to mRNA, precise workflows leave little room for deviation
-
BusinessStrikes at GSK’s Belgian sites over plans to cut 1200 jobs
Layoffs spread across R&D, manufacturing and support functions
-
BusinessMerck & Co’s US antibiotic withdrawal sends the wrong signals for combating resistance
Loss of last-resort combination Recarbrio reignites questions on how to pay for crucial but rarely-used drugs
-
ArticleA Nobel for chiral catalysts’ helping hand
This year’s laureates didn’t invent asymmetric synthesis, but filled in our understanding of how it works and how we can do it better
-
BusinessNovo goes on deal spree amid semaglutide patent expiries
Danish firm aims to bolster pipeline of weight-loss and metabolic disease therapies
-
OpinionSanctions, regulation and prices restrict access to medicines
Having medicines available when we need them is a privilege, but access more globally is complex and relies on sometimes fragile supply systems.
-
ResearchTool flags ‘lurking menace’ isomers before they become an expensive problem for drug developers
Open-source workflow developed at AstraZeneca screens drug candidates for atropisomerism
-
BusinessScreening therapeutic peptides for ‘undruggable’ proteins
Revolver Therapeutics targets transcription factors that are hard to reach with conventional drugs and antibodies
-
OpinionFeeding AI’s appetite for data
Tapping companies’ archives makes for better predictions of how proteins bind drugs, but any data inputs need to be transparent and attributed
-
PodcastDrugging the ‘undruggable’ cancer proteins & conserving the Bayeux Tapestry
How did molecular glues help crack one of cancer’s toughest targets? And we explore the chemistry behind the investigation and conservation of the Bayeux Tapestry.
-
Opinion‘Molecular glues’ are sticking it to cancer
Compounds that enhance selected protein–protein interactions to interfere with signalling or send proteins to be destroyed are making it possible to influence processes that were previously considered ‘undruggable’
-
BusinessProtein degrading breast cancer drugs navigate bumpy road to market
Camizestrant is now approved in US, UK and Europe despite uncertainty over long-term benefit, while vepdegestrant is approved in the US
-
BusinessUS approves pancreatic cancer treatment that targets ‘undruggable’ proteins
Daraxonrasib success offers hope of further approvals for Ras-inhibitor drug candidates targeting various cancers
-
PodcastAdvances in CAR-T cancer therapy & carbon materials’ hidden defects
What does recent success with bladder tumours mean for solid cancer treatment? And we discuss why scientists are rethinking how they assign peaks in spectra of carbon-based materials.
-
ResearchBenchmark flaws may be distorting AI drug-discovery leaderboards
Audit identifies subtle but consequential issues, such as conflicting labels and train–test leakage, in numerous benchmark datasets
-
FeatureCracking the ubiquitin code to unlock new drug targets
The approval of the first Protac cancer drug marks a turning point in medicine – but scientists are only beginning to decode the complex molecular language that makes it possible
-
OpinionChemistry contains multitudes
There’s room (and need) for all the various subspecies of chemical scientists
-
OpinionArtificial intelligence or clever artifice?
It’s important to be realistic about what AI can, and can’t, achieve, across the chemistry enterprise
-
ResearchStep forward for CAR-T therapy as it shows promise in solid bladder tumours
Animal tests show targeting bladder cancer specific protein can treat tumours and could cut need for surgery
-
ResearchCovalent drugs just got a new ‘spring-loaded’ warhead
Sulfur(IV) reagent allows late-stage installation of bicyclobutanes to drug molecules, expanding a limited tool box